课题基金 / 基金详情

Biosimilar Infliximab Compared to Reference Infliximab in Adults with Crohn's Disease: A Cost-Utility Analysis

Biosimilar Infliximab Compared to Reference Infliximab in Adults with Crohn's Disease: A Cost-Utility Analysis
生物仿制药英夫利昔单抗与参考英夫利昔单抗治疗成人克罗恩病的比较：成本效用分析
批准号：
389692
负责人：
Hughes Avery
金额：
$0.05万
依托单位：
University of Toronto
依托单位国家：
加拿大
项目类别：
财政年份：
2018
资助国家：
加拿大
项目状态：
已结题
起止时间：
2018-08-01 至 2019-08-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=389692&lang=en
关键词：
Ics Travel Awards

项目摘要

项目成果

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Purpose: Biologics, such as infliximab, are an important treatment option for patients with moderate-to-severe Crohn's Disease (CD), but their costs are often high. The introduction of lower-cost biosimilars offers a unique opportunity to address sustaina
期刊论文(0)
专著(0)
科研奖励(0)
会议论文